Compare Aptiv PLC (APTV) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs Illumina, Inc. — how do they compare? Aptiv PLC trades at $60.49 (market cap $12.82B), while Illumina, Inc. trades at $188.17 (market cap $28.78B). The key difference: Illumina, Inc. is far larger — about 2.2× Aptiv PLC's market cap, and Illumina, Inc. is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| APTV | ILMN | |
|---|---|---|
Market Cap | $12.82B | $28.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $76.82 | $194.33 |
52-Week Low | $52.57 | $91.00 |
Enterprise Value | $19.53B | $30.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $60.57, up 1.19% with a bearish technical signal but strong analyst support. Recent earnings beats and a consensus price target of $78.57 suggest upside potential. Revenue grew to $20.40B in 2025, though net margins compressed to 1.77%. The company announced Q2 2026 results on August 4, 2026, with expectations of $1.42 EPS.
Outlook is mixed: bullish fundamentals from earnings momentum and low P/S of 0.64 contrast with technical weakness and margin pressures. Risks include debt levels and competitive threats, but institutional buy ratings (63.6%) highlight confidence in long-term growth from automotive technology demand.
Illumina (ILMN) trades at $190.20, down 1.84% on the day but up significantly year-to-date with strong momentum. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reflect a turnaround with net income reaching $850 million in 2025 after previous losses. Recent news highlights product launches and leadership appointments, with the company scheduled to report Q2 2026 earnings on July 30, 2026.
The outlook remains positive with analyst consensus leaning bullish, though valuation multiples appear elevated. Key risks include competitive pressure from new entrants like Roche's Axelios sequencer and execution challenges in maintaining profitability growth. The upcoming earnings report will be critical for validating the current rally's sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
